Ruoyi Bio key facts
as of Oct 2026- Developer of recombinant protein drug intended for synthetic biology.
- Ruoyi Bio is valued at approximately $23.4M as of Oct 2026 (last reported valuation).
- It has raised $7.6M; the latest was Later Stage VC in Mar 2026.
- Notable investors include YuanBio Venture Capital, Kunshan Industrial Technology Research Institute, Kunshan Guoke Venture Capital, Alan Asset Management, DNE Group.
- Status: Privately Held (backing).
Ruoyi Bio's last reported valuation, Mar 2022. Nothing priced has surfaced since.
- ·Watch Ruoyi Bio: the Monday email on marks, rounds and moves
Ruoyi Bio funding rounds
No funding rounds for Ruoyi Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ruoyi Bio valuation
Ruoyi Bio's last reported valuation was $23.4 million in Mar 2022. No priced round, secondary trade or fund mark has surfaced since.
Ruoyi Bio investors
5 investors are on record for Ruoyi Bio, including YuanBio Venture Capital, Kunshan Industrial Technology Research Institute, Kunshan Guoke Venture Capital and Alan Asset Management.
About Ruoyi Bio
Developer of recombinant protein drug intended for synthetic biology. The company offers capabilities in drug discovery and biopharmaceutical development, Zinc finger protein drug delivery technology, recombinant botulinum toxin drug pipeline, and Insect cell-baculovirus platform, enabling an AI-based protein transformation project and new vitality into corporate development.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 14
- Website
- asiflyerbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.